| Literature DB >> 28228306 |
Umesh R Bilagi1, Jayaprakash Shenthar2, Manjunath Nanjappa Cholenahally3.
Abstract
BACKGROUND: HUTT test is used in evaluation of syncope. Isoprenaline and isosorbide dinitrate are used to increase the sensitivity of the test. These drugs act by different mechanisms. We aimed to compare the results of isoprenaline with isosorbide dinitrate. METHODS ANDEntities:
Keywords: HUTT; Head-up tilt test; Isoprenlaine; Isosorbide dinitrate; Syncope
Mesh:
Substances:
Year: 2016 PMID: 28228306 PMCID: PMC5319004 DOI: 10.1016/j.ihj.2016.06.007
Source DB: PubMed Journal: Indian Heart J ISSN: 0019-4832
Classification of HUTT-positive response.
| Type 1 | Heart rate falls at the time of syncope but the ventricular rate does not fall to less than 40 beats min−1 or falls to less than 40 beats min−1 for less than 10 s with or without asystole of less than 3 s. Blood pressure falls before the heart rate falls. |
| Type 2 | (A) Cardioinhibition without asystole. Heart rate falls to a ventricular rate less than 40 beats min−1 for more than 10 s but asystole of more than 3 s does not occur. Blood pressure falls before the heart rate falls. |
| Type 3 | Heart rate does not fall more than 10% from its peak at the time of syncope. |
| Exception 1. Chronotropic incompetence. No heart rate rise during the tilt testing (i.e. less than 10% from the pre-tilt rate). | |
| Exception 2. Excessive heart rate rise. An excessive heart rate rise both at the onset of the upright position and throughout its duration before syncope (i.e. greater than 130 beats min−1). |
Baseline comparison of age, sex, and drug used in HUTT.
| Parameter | Total number of subjects ( | Mean (age) | Median (age) | Std. deviation (age) | Minimum (age) | Maximum (age) | Skewness | Power for Mann–Whitney test | |
|---|---|---|---|---|---|---|---|---|---|
| Female | 44 | 17 | 15 | 6.74 | 8 | 34 | 1.01 | 0.27 | 0.22 |
| Male | 46 | 18.89 | 18 | 7.72 | 5 | 33 | 0.40 | ||
| Total | 90 | 17.97 | 16 | 7.28 | 5 | 34 | 0.67 | ||
| Passive testing | 13 | 19 | 20 | 7.41 | 10 | 31 | 0.32 | 0.91 | 0.33 |
| ISO | 51 | 16.86 | 15 | 7.17 | 5 | 34 | 0.87 | ||
| ISDN | 26 | 19.62 | 17.5 | 7.28 | 11 | 34 | 0.61 | ||
| Total | 90 | 17.97 | 16 | 7.28 | 5 | 34 | 0.67 | ||
Cross-tabulation of type of response and drug used.
| Response type | Drug used | Total | ||
|---|---|---|---|---|
| Passive testing | ISO | ISDN | ||
| Negative | 0 | 30 | 9 | 39 |
| Type 1 | 6 | 11 | 7 | 24 |
| Type 2 | 4 | 3 | 5 | 12 |
| Type 3 | 2 | 6 | 5 | 13 |
| POT | 0 | 1 | 0 | 1 |
| Pseudosyncope | 1 | 0 | 0 | 1 |
| Total | 13 | 51 | 26 | 90 |
Time to positive response with respect to passive testing, ISO, and ISDN in minutes.
| Drug used | Minimum | Maximum | Mean | Std. deviation | |
|---|---|---|---|---|---|
| Passive testing | 12 | 5 | 27 | 16.50 | 7.00 |
| ISO | 20 | 1 | 20 | 9.85 | 5.84 |
| ISDN | 17 | 2 | 15 | 7.00 | 3.35 |
Time to positive response.
| Comparison | 95% confidence interval | Effect size, | Power | |
|---|---|---|---|---|
| Passive testing versus ISDN | 0.001 | 4.85–14.35 | 0.08 | |
| Passive testing versus ISO | 0.007 | 1.96–11.34 | 0.009 | |
| ISDN versus ISO | 0.074 | −0.29 to 5.99 | 0.42 |